Hikal gets EIR for pharmaceutical facility in Panoli

12 Dec 2019 Evaluate

Hikal has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its pharmaceutical manufacturing facility in Panoli in Gujarat. The five-day detailed inspection was carried out during the period September 09, 2019 - September 13, 2019. The inspection confirmed the site to be compliant with the principles and guidelines of Current Good Manufacturing Practices (CGMP).

The inspection concluded with 'Zero' 483 observations from the auditors. The establishment inspection report received on December 12, 2019 has classified the facility under NAI (No Action Indicated) for CGMP compliance.

Hikal is engaged in R&D, manufacturing and marketing of fine chemicals for the Pharmaceutical and Agrochemical industries.


Hikal Share Price

226.90 -0.75 (-0.33%)
31-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.75
Dr. Reddys Lab 1271.05
Cipla 1510.90
Zydus Lifesciences 914.65
Lupin 2112.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×